Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma

Lancet

Volumn 353, Issue 9161, 1999, Pages 1326-

  Lohmann, Chris P ^a   Kroher, Gisela ^a   Bogenrieder, Thomas ^a   Spiegel, Detlev ^a   Preuner, Jürgen ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CASE REPORT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; OPTIC NERVE DISEASE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VISUAL IMPAIRMENT;

EID: 0033577443     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00403-1     Document Type: Article

References (5)

1. Kirkwood JM, Strawderman MH, Ernsthoff MS, Smith TJ, Borden EC, Blurn RH. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
2. Borden EC, Parkinson D. A perspective on the clinical effectiveness and tolerance of interferon-α. Semin Oncol 1998; 25 (suppl): 3-8.
3. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111:350-56.
4. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995; 113: 1041-44.
5. Taylor JL, Grossberg SE. The effects of interferon-a on the production and action of other cytokines. Semin Oncol 1998; 25 (suppl): 23-29.